- Home
- VRAX vs ONCO Comparison
VRAX vs ONCO Comparison
Compare VRAX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | ONCO |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRAX | ONCO |
|---|---|---|
| Price | $0.21 | $1.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 32.6M | 4.0M |
| Earning Date | 06-12-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.09 |
| 52 Week High | $1.14 | $7.65 |
Technical Indicators
Market Signals| Indicator | VRAX | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 52.58 |
| Support Level | $0.15 | $0.49 |
| Resistance Level | $0.24 | $1.87 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 6.15 | 62.56 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.